Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 4,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Not yet recruiting Not applicable Interventional

Improving TelePrEP Initiation and Retention Outcomes in the US: The MISTR+ Study

NCT07821671
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
No Marginal Cost Interventions, Low-Marginal Cost Interventions, Standard of Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
223,165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

NCT00000847
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children

NCT00000634
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 13 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 17, 2026, 3:32 AM EDT
Completed No phase listed Observational

Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs

NCT00006316
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2008 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Not applicable Interventional

A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3

NCT00001064
View directory record Official record
Conditions
HIV Infections
Interventions
Allogenic Dendritic Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Prevention Systems to Reduce Disparities for High Priority Populations

NCT03778164
View directory record Official record
Conditions
HIV Infections
Interventions
Fast Track Partner Services-Sexual Health Intervention
Other
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

NCT00002021
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effect of Ixazomib on the Latent HIV Reservoir

NCT02946047
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG, Ixazomib 4 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users

NCT00432926
View directory record Official record
Conditions
HIV Infections, Substance Abuse, Sexually Transmitted Diseases
Interventions
EDGE counseling, no maintenance, EDGE counseling, plus maintenance, Attention control
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS

NCT00002285
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 3:32 AM EDT
Not listed Not applicable Interventional

Smoking Cessation for People Living With HIV/AIDS

NCT01965405
View directory record Official record
Conditions
HIV, AIDS, Nicotine Dependence
Interventions
Bupropion, Brief Counseling, High-magnitude prize contingency management, Monitored support to quit smoking, No additional treatment, Prize contingency management for abstinence, Low intensity prize contingency management
Drug · Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed No phase listed Observational

Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Patients

NCT00918073
View directory record Official record
Conditions
HIV Infections, Smokers
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NCT00002073
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 3:32 AM EDT
Recruiting Phase 3 Interventional

Cefixime Clinical Trial

NCT04958122
View directory record Official record
Conditions
Syphilis, Human Immunodeficiency Virus
Interventions
Cefixime 400mg, benzathine penicillin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru

NCT00023582
View directory record Official record
Conditions
HIV Infections, Herpes Genitalis, HIV Seronegativity, Syphilis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS

NCT00002083
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Peptide T
Drug
Lead sponsor
Advanced Peptides
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 3:32 AM EDT
Recruiting Phase 3 Interventional

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805
View directory record Official record
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 1Phase 2 Interventional

Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS

NCT00079560
View directory record Official record
Conditions
HIV Infections
Interventions
dronabinol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

NCT00000969
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance

NCT00264251
View directory record Official record
Conditions
HIV Infections, Insulin Resistance, Obesity
Interventions
Weight loss through diet and exercise, Rosiglitazone insulin sensitizing agent
Behavioral · Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
20 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2007 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes

NCT06098729
View directory record Official record
Conditions
Type 1 Diabetes, Latent Autoimmune Diabetes in Adults, Pancreatitis
Interventions
Digital Exercise
Behavioral
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

NCT00002058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clofazimine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults

NCT02876315
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Redoxon VI, placebo
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
55 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 17, 2026, 3:32 AM EDT